纯度
≥ 90 % as determined by SDS-PAGE.
内毒素
Please contact us for more information.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
描述
Recombinant Mouse CCL12/MCP-5 Protein is produced by Yeast expression system. The target protein is expressed with sequence (Gly23-Gly104) of mouse CCL12/MCP-5 (Accession #NP_035461.2) fused with His tag at the C-terminus.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
（1）未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周；
（2）干粉蛋白复溶浓度建议在0.1-0.5 mg/mL，不能低于0.1mg/mL，长期储存请添加保护剂（如0.1%BSA），并分装保存，避免反复冻融；
（3）液体蛋白的保存温度及效期请参考说明书，如对液体蛋白浓度有要求，请提前咨询销售或者技术支持。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！
MCP-5/CCL12 protein promotes CCR2 chemokine receptor binding and contributes to physiological processes such as angiogenesis, inflammation, and monocyte chemotaxis. It is located extracellularly and is widely expressed in tissues such as the central nervous system. CCL12 attracts eosinophils, monocytes, and lymphocytes but not neutrophils, and it is a potent monocyte active chemokine that signals through CCR2, and involved in allergic inflammation and the host response to pathogens and may play a pivotal role during early stages of allergic lung inflammation.
